2月12日,Mylan宣布在美国正式上市Wixela Inhub(氟替卡松/沙美特罗)。Wixela Inhub是GSK明星重磅品种Advair Diskus的首个仿制药,在1月30日获批每日2次用于治疗4岁以上哮喘患者以及慢性阻塞性肺病(COPD)患者的气管阻塞。 葛兰素史克Advair全球销售额(百万英镑) Mylan同时公布了3个不同规格Wixela的批发商采购价格(who...
申请类型 ANDA 申请号 208891 药品名称 WIXELA INHUB 活性成分 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE 活性成分中文 暂无权限 执行时间 2019-02-06 持有公司 MYLAN 说明书 下载 VIP试用医疗器械查询APP下载客服中心常见问题数据可视化数据分析挖掘系统网站地图业务介绍友情链接 400-678-0778 投诉...
Background:Wixela Inhub is a generic version of Advair Diskus recently approved by the U.S. Food and Drug Administration. The Inhub inhaler delivers fluticasone propionate (FP)/salmeterol in a dry powder formulation. The goals of our studies were to demonstrate that the Inhub inhaler can be ...
All three dosage strengths of Wixela Inhub will be offered at a wholesale acquisition cost of up to 70% less than Advair Diskus and the authorized generic equivalent.doi:10.1007/s40267-019-00686-wHannah A. BlairSpringer NatureDrugs & Therapy Perspectives...
asthmaCOPDdry powder inhalerflow rateBackground: Wixela (TM) Inhub (TM) is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair Diskus(R) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub and Advair Diskus are...
2月12日, Mylan 宣布在美国正式上市Wixela Inhub(氟替卡松/沙美特罗),这是GSK重磅品种舒利迭的首个仿制药,用于治疗4岁以上哮喘患者以及慢性阻塞性肺病(COPD)患者的气管阻塞。首仿药价直降70%,降的太厉害, 恒瑞 的还在研发路上,看来是没戏了。
Background: Wixela (R) Inhub (R) is a dry powder inhaler approved as a generic equivalent to Advair (R) Diskus (R) (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at confirming the ...
Background: Wixela Inhub was developed to deliver inhaled fluticasone propionate/salmeterol (FP/S) combination as a substitutable generic equivalent to Advair Diskus. These studies aimed to confirm the pharmacokinetic bioequivalence (BE) of FP/S after single doses of Wixela Inhub (test [T]) and...